Statement Of Cash Flows [Abstract]

Tchaikapharma High Quality Medicines AD - Filing #6023734

Concept	As at 2021-12-31	2021-01-01 to 2021-12-31	As at 2020-12-31	2020-01-01 to 2020-12-31	As at 2019-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Classes of cash receipts from operating activities [abstract]
Receipts from sales of goods and rendering of services	—	33 931 BGN	—	35 208 BGN	—
Classes of cash payments from operating activities [abstract]
Payments to suppliers for goods and services	—	22 965 BGN	—	22 940 BGN	—
Payments to and on behalf of employees	—	5 518 BGN	—	4 802 BGN	—
Other cash payments from operating activities	—	3,000 BGN	—	4,000 BGN	—
Income taxes paid (refund), classified as operating activities	—	218,000 BGN	—	352,000 BGN	—
Other inflows (outflows) of cash, classified as operating activities	—	3 180 BGN	—	3 613 BGN	—
Cash flows from (used in) operating activities	—	2 023 BGN	—	3 486 BGN	—
Cash flows from (used in) investing activities [abstract]
Purchase of other long-term assets, classified as investing activities	—	1 573 BGN	—	2 907 BGN	—
Cash flows from (used in) investing activities	—	1 573 BGN	—	2 907 BGN	—
Cash flows from (used in) financing activities [abstract]
Proceeds from borrowings, classified as financing activities	—	199,000 BGN	—	200,000 BGN	—
Repayments of borrowings, classified as financing activities	—	201,000 BGN	—	201,000 BGN	—
Payments of lease liabilities, classified as financing activities	—	459,000 BGN	—	358,000 BGN	—
Dividends paid, classified as financing activities	—	200,000 BGN	—	196,000 BGN	—
Other inflows (outflows) of cash, classified as financing activities	—	204,000 BGN	—	- BGN	—
Cash flows from (used in) financing activities	—	457,000 BGN	—	555,000 BGN	—
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes	—	7,000 BGN	—	24,000 BGN	—
Cash and cash equivalents	57,000 BGN	—	64,000 BGN	—	40,000 BGN